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Introduction
The extracellular signal–regulated kinase (ERK) 5 is a mem-
ber of the MAPKs (Lee et al., 1995; Zhou et al., 1995). The 
N-  terminal kinase domain of ERK5 is highly homologous to the 
prototypical MAPKs ERK1/2. However, ERK5 is selectively 
activated by its upstream kinase MEK5 (English et al., 1995) 
and ERK5-null mice are embryonic lethal (Hayashi and Lee, 
2004), suggesting that ERK5 has unique biological functions 
that cannot be compensated for by ERK1/2. Stimulation of 
ERK5 regulates neuronal survival, muscle cell differentiation, 
and cellular proliferation and transformation (Kato et al., 1998; 
Pearson et al., 2001; Watson et al., 2001; Liu et al., 2003; 
Shalizi et al., 2003). Hyperactivity of the ERK5 pathway is as-
sociated with highly aggressive forms of breast and prostate 
cancers (Esparis-Ogando et al., 2002; Mehta et al., 2003).
Mechanisms for ERK5 regulation of proliferation are not 
well understood. However, several targets of ERK5 have been 
identifi  ed, including nuclear factor κB (NFκB), c-myc, and 
  cyclin D, all of which are potential regulators of proliferation 
(Wang and Tournier, 2006). NFκB is of particular interest because 
it regulates the G1–S transition of the cell cycle and is required 
for oncogenic transformation by Ras (Finco et al., 1997; Hinz et al., 
1999). Mutations that result in constitutive activation of NFκB 
are common in epithelial tumors, tumor cell lines, and lymphoid 
malignancies. These NFκB mutations cause increased prolifera-
tion rates and metastatic capacity (Karin et al., 2002). Interest-
ingly, ERK5-mediated activation of NFκB promotes cellular 
transformation in NIH 3T3 cells (Pearson et al., 2001).
To elucidate mechanisms for ERK5 regulation of cellular 
proliferation, we investigated the importance of ERK5 in cell 
cycle progression. We examined ERK5 activity at different 
stages of the cell cycle and discovered that ERK5 is activated in 
a cell cycle–dependent manner, with maximal activation at G2–M. 
Evidence is presented supporting a critical role for ERK5 in 
the G2–M progression. Our data also identify NFκB-mediated 
transcription as a key downstream mechanism by which ERK5 
regulates the G2–M phase transition.
Results
ERK5 is activated during the G2–M phases 
of the cell cycle
Although ERK5 plays a pivotal role in growth factor–induced 
cellular proliferation (Kato et al., 1998), its role in cell cycle 
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regulation is unclear. To determine whether ERK5 is activated 
at specifi  c stages of the cell cycle, Western analysis using an 
anti-ERK5 antibody was performed on HeLa cells arrested at 
different stages of the cell cycle. The cell cycle stage for each 
treatment was confi  rmed by fl  ow cytometry analysis (FACS; 
Fig. 1 A and not depicted). Cell cycle arrest at M phase was fur-
ther confi  rmed by Western analysis and immunostaining using 
an antibody that recognizes phosphorylated mitosis-specifi  c 
marker proteins (p-MPM-2; Fig. 1, A and B). Treatment of cells 
with the microtubule destabilizing agent nocodazole, which ar-
rests cells at the start of the M phase, caused a reduced electro-
phoretic mobility (phosphorylation shift) of ERK5 (Fig. 1 A), 
indicative of ERK5 activation (Kato et al., 1998). In contrast to 
M phase arrest, there was very little activation of ERK5 in asyn-
chronized cells or when cells were arrested at G1, S, or the G1–S 
boundary of the cell cycle (Fig. 1, A and D).
Nocodazole activation of ERK5 was apparently due to the 
arrest of cells at M phase. Arrest of HeLa cells at M phase with 
taxol also caused ERK5 activation (unpublished data). In addi-
tion, we treated primary cultured cortical neurons from newborn 
rats with nocodazole. In contrast to HeLa cells, nocodazole did 
not induce ERK5 phosphorylation in these postmitotic cortical 
neurons, although these cells express abundant ERK5 that is 
readily activated by brain-derived neurotrophic factor (Fig. 1 C). 
Moreover, we collected mitotic HeLa cells by shaking them off 
the culture dish 9 h after thymidine release (mitotic; Fig. 1 D). 
ERK5 was phosphorylated in this highly enriched mitotic cell 
population but not in nonmitotic control cells. Finally, ERK5 
activation in mitotic and in nocodazole-arrested M phase HeLa 
cells was confi  rmed by a direct kinase assay (Fig. 1 D). MEK5, 
the only known kinase that phosphorylates and activates ERK5 
(English et al., 1995), was also activated in mitotic and nocodazole-
treated HeLa cells (Fig. 1 E).
We also measured ERK5 activation as S phase–synchro-
nized HeLa cells progressed to M phase. When HeLa cells were 
released from a single-thymidine block that synchronizes cells 
at early S phase, ERK5 phosphorylation was detectable 6 h after 
thymidine release. At this time, there was a small increase in the 
number of cells harboring 4n DNA but very few mitotic cells 
(Fig. 2, A–C). Mitotic cells were identifi  ed by both positive 
  immunostaining of p-MPM-2 and the condensed nuclear mor-
phology typical of mitotic cells (Fig. 1 B). ERK5 phosphorylation 
peaked 8 h after release from a single-thymidine block, when 
the majority of cells (>84%) had 4n DNA content, but only 5% 
of the cells were mitotic. Similar observations were made when 
HeLa cells were synchronized with a double-thymidine block 
(Fig. 2, D–F). ERK5 phosphorylation was readily detectable 
9 h after thymidine release, a time when the majority of cells 
Figure 1.  ERK5 is activated during G2–M 
phases of the cell cycle. (A) ERK5 is activated 
in a cell cycle–dependent manner. HeLa cells 
were treated with cell cycle–arresting drugs 
described in Materials and methods or left un-
treated as an asynchronous (ASY) population. 
M phase arrest was veriﬁ  ed by Western analy-
sis for p-MPM-2 and by FACS analysis of 
DNA content. Cell lysates were prepared for 
Western analysis using a polyclonal antibody 
against ERK5. Phosphorylated ERK5 appears 
as a shift in ERK5 mobility, indicative of ERK5 
activation.  β-Actin was used as a loading 
control. (B) Mitotic cells are identiﬁ  ed by posi-
tive p-MPM-2 staining (red), and condensed 
nuclear morphology was visualized after stain-
ing with Hoechst 33342 (blue). (C) 0.5 μg/ml 
nocodazole treatment does not induce ERK5 
phosphorylation in postmitotic neurons cul-
tured from newborn rat cortex, suggesting that 
ERK5 activation by nocodazole is speciﬁ  c to 
cycling cells. Brain-derived neurotrophic factor 
(BDNF) stimulation of ERK5 phosphorylation 
was used as a positive control for ERK5 in cor-
tical neurons. (D) The kinase activity of ERK5 is 
stimulated in mitotic and nocodazole-treated 
HeLa cells. Mitotic cells were gently shaken off 
the tissue culture ﬂ  asks and collected 9 h after 
release from a double-thymidine block. The 
cells remaining attached to the ﬂ   asks were 
collected as a “nonmitotic” control. HeLa cells 
were also treated with 0.5 μg/ml nocodazole 
for 12 h or vehicle as an asynchronous control. 
Cell lysates were subjected to Western analy-
sis for ERK5 and β-actin (top) or an immuno-
precipitation-coupled in vitro kinase assay 
for  ERK5 using GST-MEF2C as a substrate 
(bottom). (E) The kinase activity of MEK5 is 
stimulated in mitotic and nocodazole-treated 
HeLa cells. Cell lysates were collected as in D 
and subjected to Western analysis for MEK5 as loading control (top) or an immunoprecipitation-coupled in vitro kinase assay for MEK5 using MBP as 
a substrate (bottom). The anti-MEK5 antibody also cross-reacted nonspeciﬁ  cally with a protein band above MEK5.ERK5–NFκB PATHWAY IN G2–M REGULATION • CUDE ET AL. 255
ERK5 is critical for G2–M progression
The temporal profi  le of ERK5 activation suggests that it might 
play a role in G2–M progression. To test this hypothesis, we ex-
pressed various constructs that either activate or inhibit ERK5 
signaling and evaluated their effects on mitosis. Expression of 
constitutive-active (ca) MEK5 with wild-type (wt) ERK5 in 
HeLa cells, which activates ERK5 in transfected cells, increased 
the number of cells that are positive for the mitotic markers 
p-MPM-2 and p-histone H3 (Fig. 3 A). These cells also displayed 
the typical mitotic nuclear morphology (unpublished data). This 
suggests that ectopic activation of ERK5 signaling is suffi  cient 
to increase mitotic index in an asynchronous population.
In a separate set of experiments, HeLa cells were trans-
fected as in Fig. 3 A and treated 24 h after transfection with thy-
midine to synchronize cells at S phase. The mitotic index in the 
transfected cell population was determined 12 h after thymidine 
release. Constitutive activation of ERK5 signifi  cantly increased 
the mitotic index (Fig. 3 B), suggesting that more of these cells 
progressed from S phase into the mitotic phase. In contrast, tran-
sient expression of dominant-negative (dn) ERK5, which blocks 
ERK5 signaling, reduced the mitotic index. A similar experi-
ment was performed using siRNA to suppress ERK5 expression 
and inhibit ERK5 signaling (Fig. 3 C). Transfection of the ERK5 
siRNA greatly reduced ERK5 expression 48 h later (Fig. 3 C, 
top). When HeLa cells were synchronized by thymidine treatment 
Figure 2.  ERK5 is activated when HeLa cells enter G2–M after release from 
a thymidine block. HeLa cells were released from a single- (A–C) or double- 
(D–F) thymidine block. (A and D) Western analysis showing ERK5 phosphoryl-
ation as cells enter G2–M. (B and E) FACS analysis for 2n and 4n DNA 
content after thymidine release. (C and F) Percentage of mitotic index (i.e., 
percentage of mitotic cells). Data are presented as means ± SEM.
Figure 3.  ERK5 is critical for G2–M progression. (A) Constitu-
tive activation of ERK5 is sufﬁ  cient to increase mitotic index in 
asynchronous HeLa cells. HeLa cells were transfected with 
plasmid DNA encoding caMEK5 + wtERK5 to activate ERK5. 
The vector control (Vec) or dnERK5 were used as controls. 
Cells were also cotransfected with EGFP to identify transfected 
cells. Mitotic cells in the transfected cell population (GFP
+) 
were identiﬁ  ed 48 h after transfection by both condensed 
  mitotic nuclear morphology and positive staining for mitotic 
markers p-MPM-2 or p-histone H3. (B) Constitutive activation 
of ERK5 increases, whereas blocking ERK5 reduces, mitotic 
index. HeLa cells were transfected with plasmid DNA as in A. 
Cells were treated 24 h later with thymidine for 14–16 h to 
synchronize at S phase. Mitotic index in transfected cells 
(GFP
+) was quantiﬁ  ed 12 h after thymidine release. (C) siRNA 
silencing of ERK5 inhibits mitosis in transfected cells (GFP
+). 
HeLa cells were transfected with an ERK5 siRNA (siERK5) or 
a control nonsilencing siRNA (NS). A mock transfection (C) 
was included as a negative control. Anti-ERK5 Western analy-
sis illustrates siRNA suppression of ERK5 protein 48 h after 
transfection. (D) Time course for adenoviral expression of GFP 
and dnMEK5. HeLa cells were synchronized at S phase with 
thymidine and then infected with an adenovirus expressing 
both GFP and dnMEK5 under separate promoters 2 h after 
thymidine release. GFP expression was detected by GFP ﬂ  uo-
rescence, whereas dnMEK5 expression was detected by 
Western analysis. (E) Adenoviral inhibition of ERK5 at G2–M 
reduces mitotic index. HeLa cells were released from a thymi-
dine block and infected with dnMEK5 or a control adenovirus 
2 h later. The mitotic index in adenovirus-infected cells (GFP
+) 
was determined 12 h after the second thymidine release (i.e., 
10 h after infection). Data are presented as means ± SEM. 
**, P < 0.01.
(>86%) were in G2–M phases harboring 4n DNA, whereas 
only 17% of the cells were p-MPM-2
+ mitotic cells. We con-
clude that ERK5 is activated at both G2 and M phases.JCB • VOLUME 177 • NUMBER 2 • 2007  256
24 h after transfection, transfection of ERK5 siRNA signifi  -
cantly reduced mitotic index (Fig. 3 C, bottom).
In the experiments described in Fig. 3, HeLa cells were 
synchronized at early S phase with thymidine 1 d after transfec-
tion, well before a considerable amount of transfected ERK5 
was expressed (unpublished data) or siRNA reduction of endo-
genous ERK5 protein occurred. Furthermore, ERK5 activation at 
G1 and S phases was almost undetectable in HeLa cells. There-
fore, data in Fig. 3 (B and C) suggest that ERK5 signaling may 
regulate mitotic entry and/or progression. To strengthen this 
conclusion, we designed an experiment to block ERK5 activity 
from G2 to M phases onward to avoid any potential interference 
with the G1 and S phases. We took advantage of the fact that 
adenoviral-mediated gene expression, monitored by GFP ex-
pression and Western analysis, occurs 6 h after viral infection 
(Fig. 3 D). HeLa cells were synchronized in early S phase by a 
single-thymidine treatment. 2 h after release from thymidine, 
cells were infected with an adenovirus that expresses both GFP 
and dnMEK5 (Watson et al., 2001). This allowed expression 
of dnMEK5 starting from G2 and continuing onward. The 
dnMEK5 used in this experiment inhibits the signaling of ERK5 
but not other related MAPKs (Kato et al., 1997; Cavanaugh 
et al., 2001; Watson et al., 2001). Expression of the adenoviral 
dnMEK5 signifi  cantly reduced mitotic index in adenovirus-
  infected cells 12 h after thymidine release (Fig. 3 E). Together, 
data in Fig. 3 suggest that ERK5 regulates G2–M progression.
ERK5 activates NF𝗋B at G2–M
Activation of ERK5 regulates several downstream targets, 
including NFκB (Pearson et al., 2001), a transcription factor 
implicated in cellular proliferation. To determine whether ERK5 
activation at G2–M leads to NFκB activation, we transfected 
HEK293 cells with an NFκB-luciferase reporter to monitor 
NFκB activity. Cells were also cotransfected with dnERK5 to 
block endogenous ERK5 signaling. We used HEK293 cells to 
measure NFκB activities because the basal NFκB activity in 
HeLa cells is very high (unpublished data). As in HeLa cells, 
ERK5 phosphorylation was mainly detected in nocodazole-
  arrested M phase HEK293 cells (unpublished data). The NFκB 
reporter gene was activated in HEK293 cells after nocodazole 
treatment or when cells were released from a single-thymidine 
block for 12 h (Fig. 4 A). Importantly, expression of dnERK5 
signifi  cantly reduced NFκB-luciferase activity under both 
conditions. Although the NFκB reporter was only activated 150% 
12 h after thymidine release, this stimulation was statistically sig-
nifi  cant and consistent with the mitotic index of 22% in thymidine-
released cells compared with 68% in nocodazole-treated cells. 
In addition, NFκB-luciferase reporter activities were increased 
in mitotic cells compared with nonmitotic control cells after 
the mitotic shake off (Fig. 4 B).
Similar experiments were performed using an NFκB 
DNA binding ELISA assay. As a positive control, HEK293 
cells were transfected with caMEK5 + wtERK5 to activate 
ERK5. NFκB DNA binding was activated in cells expressing 
caMEK5 with ERK5 and in cells treated with nocodazole for 
12 h (Fig. 4 C). Expression of dnERK5 signifi  cantly inhibited 
NFκB DNA binding activities afforded by caMEK5 expression 
or nocodazole treatment. Finally, nocodazole treatment also 
increased the DNA binding activity of NFκB measured by a 
conventional gel shift assay, and the expression of dnMEK5 
prevented this increase (Fig. 4 D). These data suggest that stim-
ulation of ERK5 at G2–M causes activation of NFκB.
ERK5 activates NF𝗋B by causing I𝗋B 
degradation, a process that is regulated 
by ribosomal S6 kinase 2 (RSK2)
In resting cells, the p50/p65 heterodimer of NFκB is normally 
sequestered in the cytoplasm by the inhibitor protein, IκB (Karin 
et al., 2002). Upon stimulation, IκB is phosphorylated on 
serine-32 and serine-36 residues. This targets IκB for proteasome-
mediated degradation, thereby releasing NFκB and allowing its 
nuclear translocation and DNA binding (Beg et al., 1992). Data 
in Fig. 4 demonstrated that ectopic ERK5 activation or M phase 
arrest by nocodazole treatment increases NFκB binding to DNA, 
Figure 4.  ERK5 activation at G2–M leads to NF𝗋B stimulation. (A) NFκB-
luciferase activity is increased in HEK293 cells 12 h after thymidine   release 
or after nocodazole (NOC) treatment. HEK293 cells were cotransfected 
with an NFκB-luciferase reporter and dnERK5 or vector control (Vec) and 
treated with 2 mM thymidine for 16 h to synchronize at S phase. Luciferase 
activity was measured 12 h after thymidine release. Alternatively, cells 
were treated with 0.5 μg/ml nocodazole 36 h after transfection, and 
  reporter gene activity was assayed 12 h later. (B) NFκB-luciferase activity 
is increased in mitotic cells. HEK293 cells were treated with 2 mM thymi-
dine for 16 h. The thymidine block was released for 8 h, during which cells 
were transfected with an NFκB-luciferase reporter. The cells were then 
treated with thymidine again for 16 h. Mitotic cells were gently shaken off 
the tissue culture dish 9 h after release from the second thymidine block, 
and NFκB-luciferase activity was measured. Cells that were still attached to 
the culture dish were used as nonmitotic control cells. The luciferase activity 
in both A and B was normalized to the cotransfected β-gal. (C) NFκB DNA 
binding ELISA assay. HEK293 cells were transfected with vector control, 
caMEK5, wtERK5, or dnERK5 as indicated. NFκB-DNA binding ELISA 
  assay was performed 48 h later. 0.5 μg/ml nocodazole treatment was 
performed 36 h after transfection. (D) NFκB-DNA binding measured by an 
electrophoretic mobility shift assay. HeLa cells were transfected with Vec or 
dnMEK5 and treated with nocodazole for 12 h as in C. The TNFα-treated 
sample was used as a positive control and subjected to supershift analysis 
to conﬁ  rm NFκB-DNA binding speciﬁ  city. Histone-H1 Western was used as 
a loading control. Data are presented as means ± SEM. **, P < 0.01; 
***, P < 0.001.ERK5–NFκB PATHWAY IN G2–M REGULATION • CUDE ET AL. 257
suggesting that NFκB activation may be due to IκB degradation. 
Indeed, IκB protein levels were reduced in nocodazole-treated 
HeLa cells, and its degradation was partially blocked by dnERK5 
(Fig. 5 A). This suggests that ERK5 regulates the degradation of 
IκB during G2–M phases of the cell cycle.
Although ERK5 activity is required for NFκB activation, 
ERK5 does not directly bind to or modulate either IκB or NFκB 
(unpublished data). This suggests that another kinase may be 
acting as a mediator between ERK5 and IκB. The most studied 
IκB kinases are the IKK family of enzymes (Hayden and Ghosh, 
2004). We monitored IKK activation at G2 and M phases by 
Western analysis using an antibody that recognizes phosphory-
lated and activated IKK (p-IKK). IKK was phosphorylated 3–6 h 
after release from double-thymidine block (Fig. 5 B), a time 
when the majority of cells were in S phase and ERK5 was not 
activated. IKK phosphorylation in S phase is consistent with a 
role for NFκB in G1–S control. However, IKK was not phos-
phorylated 9–12 h after thymidine release, when the majority 
of cells were in G2–M and ERK5 was maximally activated. 
Furthermore, although ERK5 was activated in a cell population 
enriched with mitotic cells (Fig. 1 D), IKK phosphorylation was 
not detectable in this same preparation (Fig. 5 B). These data 
indicate that IKK does not mediate ERK5 activation of NFκB 
at G2–M phases of the cell cycle.
RSK1 and RSK2 are downstream targets of the ERK1/2 
pathway that can directly phosphorylate IκB, thereby targeting 
IκB for degradation (Ghoda et al., 1997; Schouten et al., 1997). 
It has been reported that ERK5 activates RSK2 in NIH 3T3 
cells and in neurons (Pearson et al., 2001; Watson et al., 2001). 
To determine whether RSK1 or RSK2 is activated by ERK5 in 
our system, HEK293 cells were transfected with caMEK1, 
which is suffi  cient to activate endogenous ERK1/2, or with 
Figure 5. ERK5-dependent  I𝗋B degradation 
and NF𝗋B activation during G2–M is mediated 
by RSK2 but not IKK. (A) The IκB protein is de-
graded in M phase–arrested cells in an ERK5-
dependent manner. HeLa cells were transfected 
with vector control (Vec) or dnERK5 and treated 
with 0.5 μg/ml nocodazole for 12 h. IκB 
protein levels were normalized against β-actin. 
(B) In contrast to ERK5, IKK is not activated at 
G2–M or in mitotic cells. HeLa cells were syn-
chronized by a double-thymidine block. The 
activation of endogenous IKK at various times 
after thymidine release was analyzed by anti–
phospho-IKK Western blotting (left). The pro-
tein level for IKK was analyzed by anti-IKK 
immunoblotting. Alternatively, the same set of 
lysates prepared from mitotic and nonmitotic 
cells described in Fig. 1 D were subjected to 
Western analysis for IKK phosphorylation 
(right). (C) ERK5 increases the kinase activity 
of RSK2, but not RSK1, toward a known sub-
strate CREBtide. HEK293 cells were trans-
fected with vector control or caMEK5 + ERK5. 
Endogenous RSK1 or RSK2 was immuno-
precipitated, and their kinase activities were 
measured by an in vitro kinase assay using 
CREBtide as a substrate. caMEK1, which acti-
vates endogenous ERK1/2, was used as a 
positive control for both RSK1 and RSK2. 
(D) RSK2 is activated at G2–M. Endogenous 
RSK2 was immunoprecipitated from HeLa cells 
released from a double-thymidine block and its 
kinase activity measured as in C. (E) 0.5 μg/ml 
nocodazole treatment for 6 h induces nuclear 
translocation of ERK5 and RSK2 in HeLa cells. 
Data were confocal images after immuno-
staining. Arrows point to two cells with nu-
clear staining for ERK5 and RSK2. (F) ERK5 
and RSK2 interact with each other. HeLa cells 
were treated with 0.5 μg/ml nocodazole 
(NOC) or vehicle control (Veh) for 12 h. Endo-
genous RSK2 was immunoprecipitated (IP) from 300 μg of total cell lysates, and its association with ERK5 was analyzed by anti-ERK5 Western blotting (IB). 
Anti-RSK2 Western blotting was performed on the same blot as a loading control of the immunoprecipitated material. Immunoprecipitation using an 
unrelated antibody (anti–β-actin) was used as a negative control for the coimmunoprecipitation. (G) Both constitutive ERK5 activation and nocodazole treat-
ment increase RSK2 phosphorylation of IκB. HEK293 cells were transfected with caMEK5 + ERK5, dnERK5, or Vec (top). Alternatively, HEK293 cells were 
treated with nocodazole for 0 or 12 h (bottom). Endogenous RSK2 was immunoprecipitated and its kinase activity toward IκB measured by an in vitro ki-
nase assay using human recombinant IκB protein as a substrate. (H) NFκB-dependent transcription, either induced by constitutive ERK5 activation or by 
nocodazole treatment, requires RSK2 activity. HEK293 cells were transfected with a NFκB-luciferase reporter gene together with dnRSK2 or vector control. 
Cells were also cotransfected with caMEK5 + ERK5 or vector control or treated with nocodazole to stimulate NFκB. (I) Expression of dnRSK2 blocks mitotic 
entry induced by constitutive activation of ERK5. HeLa cells were transfected with various plasmid DNA as indicated. Cells were also cotransfected with 
EGFP to identify transfected cells. Cells were treated 24 h later with thymidine for 16 h. Mitotic index in transfected cell population (GFP
+) was quantiﬁ  ed 
12 h after thymidine release. Data are presented as means ± SEM. **, P < 0.01; ***, P < 0.001.JCB • VOLUME 177 • NUMBER 2 • 2007  258
caMEK5 + wtERK5 to activate ERK5 signaling. Constitutive 
activation of the ERK1/2 pathways increased the activity of both 
RSK1 and RSK2, whereas constitutive activation of ERK5 only 
activated RSK2 (Fig. 5 C). These data suggest that RSK2, but 
not RSK1, may mediate ERK5 activation of NFκB.
To determine whether RSK2 is activated at G2 and M 
phases, the kinase activity of endogenous RSK2 was measured 
in HeLa cells synchronized by double-thymidine block. Like 
ERK5, RSK2 was activated 9 h after thymidine release, when 
the majority of cells were at G2–M (Fig. 5 D). RSK2 was also 
activated in the cell population enriched with mitotic cells 
(unpublished data). Furthermore, RSK2 colocalized with ERK5 
in nocodazole-treated HeLa cells (Fig. 5 E). In control cells, both 
RSK2 and ERK5 were localized in the cytosol. Nocodazole 
treatment for 6 h induced nuclear translocation of both proteins 
in some cells. Moreover, immunoprecipitation of endogenous 
RSK2 isolated from nocodazole-treated HeLa cells pulled down 
both phospho-ERK5 and nonphospho-ERK5 protein (Fig. 5 F), 
suggesting a physical interaction between ERK5 and RSK2. 
This is consistent with a recent report documenting an inter-
action between ERK5 and RSK2 (Ranganathan et al., 2006).
The kinase activity of endogenous RSK2 toward IκB was 
directly measured by an in vitro kinase assay. RSK2 phos-
phorylation of IκB protein increased 2- or 1.6-fold in HeLa cells 
expressing caMEK5 + ERK5 or in nocodazole-treated HeLa 
cells, respectively (Fig. 5 G). Expression of dnERK5 reduced 
basal RSK2 kinase activity toward IκB by 60%. Furthermore, 
expression of dnRSK2 abrogated NFκB activation induced by 
nocodazole or by expression of caMEK5 + ERK5 (Fig. 5 H).
To test the functional consequence of RSK2 activation by 
ERK5 in G2–M regulation, HeLa cells were transfected and 
treated as in Fig. 3 B. A dnRSK2 was transfected to inhibit 
RSK2 signaling. As shown in Fig. 3 B, ectopic activation of 
ERK5 increased the mitotic index 12 h after thymidine release. 
This increase was blocked by coexpression of dnRSK2 (Fig. 5 I). 
Together, these data suggest that RSK2 is activated down-
stream from ERK5 at G2–M phases of the cell cycle and that 
ERK5 activates NFκB via RSK2-dependent IκB phosphoryla-
tion and degradation.
NF𝗋B regulates mitotic entry
The specifi  c NFκB inhibitors SN50 and helenalin were used to 
determine whether NFκB-dependent transcription is necessary 
for G2–M progression. As a positive control, we confi  rmed that 
SN50 and helenalin block NFκB-stimulated transcription after 
TNFα treatment (unpublished data). SN50 and helenalin were 
added to HeLa cells 8 h after release from a single-thymidine 
block (Fig. 6) or 6 h after a double-thymidine block (Fig. 7) to 
interfere with the G2–M, but not G1–S, function of NFκB. Both 
SN50 and helenalin greatly decreased the mitotic index 12 h 
  after release from a single-thymidine block (Fig. 6, A and B).
We determined whether there is a critical time when 
blocking NFκB signaling inhibits mitosis. SN50 was added 
8 or 10 h after release from a single-thymidine block, times 
corresponding to the beginning and midpeak of appearance of 
mitotic cells, respectively. Interestingly, addition of SN50 8 h, 
but not 10 h, after thymidine release reduced the mitotic index 
(Fig. 6 C). Similar results were obtained when actinomycin D 
was used to block general transcription (unpublished data). 
These data suggest that NFκB-mediated transcription regulates 
G2–M progression.
The kinetics for the effect of helenalin on mitosis were 
also examined. HeLa cells were synchronized with a double-
thymidine block and treated with helenalin 6 h after thymidine 
release to inhibit NFκB from G2 phase onward. Helenalin did 
not affect the rate of appearance of cells harboring 4n DNA 
9 h after thymidine release (Fig. 7 A), suggesting that DNA 
synthesis and S phase completion were unaffected. However, 
there was a delay in the reappearance of 2n DNA–containing 
cells (G0–G1) and in the disappearance of 4n DNA–containing 
cells (G2–M) 9–14 h after thymidine release, suggesting that cells 
were staying at G2–M longer. This could have resulted from 
a delay in mitotic entry, meaning cells spent more time in G2, 
or a delay in mitotic exit in which cells stayed in M phase 
longer. Because the majority of the cells still harbored 4n DNA 
and were in G2 or M phases of the cell cycle 10 h after release 
from a single-thymidine block (Fig. 2 B), the fact that treat-
ment with SN50 at this time did not affect the mitotic   index 
Figure 6.  Effect of pharmacological inhibition of NF𝗋B on mitosis. HeLa 
cells were released from a single-thymidine block. (A) Addition of SN50 or 
helenalin (HEL) at the start of G2 reduces mitotic index monitored 12 h 
after thymidine release. HeLa cells were left untreated (UT) or treated with 
18 μM SN50 peptide, control peptide (CON), or 1 μM helenalin 8 h 
after thymidine release. (B) Dose response of helenalin inhibition of mitosis. 
(C) Addition of SN50 8 h, but not 10 h, after thymidine release reduces 
mitotic index. Veh, vehicle control. Data are presented as means ± SEM. 
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(Fig. 6 C) favors the former explanation. To more clearly dis-
tinguish between these two possibilities, taxol or nocodazole 
was included to block mitotic exit and trap mitotic cells so any 
defects in mitotic entry can be detected unambiguously. Hele-
nalin treatment in the presence of taxol or nocodazole delayed 
accumulation of mitotic cells (Fig. 7, B and C), suggesting 
that NFκB activity is required for mitotic entry.
In addition to the pharmacological inhibitors, we used an 
adenovirus encoding a nondegradable IκB super repressor 
(SR) mutant protein to specifi  cally block NFκB activation 
(Wang et al., 1996). When infected 2 h after release from a 
single-thymidine block, the adenoviral IκB SR was abun-
dantly expressed 6 h later, when cells enter mitosis (Fig. 7 D). 
Expression of IκB SR from G2 phase onward delayed the 
appearance of mitotic cells after HeLa cells were released 
from a double-thymidine block (Fig. 7 E). This reduction in 
mitotic index persisted when mitotic exit was blocked by 
taxol. Similar to treatment with helenalin, expression of IκB 
SR did not affect the rate of initial appearance of cells harboring 
4n DNA between 6 and 9 h (Fig. 7 F), suggesting that DNA 
synthesis and S phase completion were unaffected. However, 
the disappearance of 4n DNA–containing cells and reappear-
ance of 2n DNA–containing cells slowed down. Together, 
data in Fig. 7 demonstrate that blocking NFκB signaling 
  delays mitotic entry.
ERK5 promotion of G2–M transition 
requires NF𝗋B
To establish a direct link between ERK5 and NFκB at G2–M 
progression, HeLa cells were transfected with caMEK5 + 
wtERK5. 1 d later, cells were synchronized at S phase by a 
  single-thymidine block. 2 h after thymidine release, cells were 
infected with the IκB SR adenovirus to selectively block NFκB 
signaling at G2–M. Expression of this IκB SR at G2–M greatly 
reduced the mitotic index (Fig. 8 A). Similar results were ob-
tained when SN50 or helenalin was used to inhibit NFκB sig-
naling at G2–M (Fig. 8 B). This supports the hypothesis that 
ERK5 activation of NFκB is critical for G2–M progression dur-
ing the cell cycle.
NF𝗋B regulates the transcription of genes 
critical for mitotic entry
To identify target genes of the ERK5–NFκB pathway that regu-
late G2–M transition, quantitative RT-PCR was performed to 
investigate the effect of blocking NFκB on the transcription 
of several genes known to be critical for mitotic entry. These 
  include cyclin B1 and B2 (Pines and Hunter, 1990), polo-like 
kinase-1 (Plk-1; Barr et al., 2004), and protein phosphatase 
cdc25B (Nilsson and Hoffmann, 2000). HeLa cells were syn-
chronized by a double-thymidine block and then infected with 
control or IκB SR adenovirus at the time of thymidine release to 
inhibit NFκB from G2 phase onward. The transcripts of cyclin 
B1, cyclin B2, Plk-1, and cdc25B were increased 9 h after thy-
midine release (Fig. 9, A–D). Up-regulation of these transcripts 
was inhibited by IκB SR. The incomplete suppression of tran-
scription suggests that other factors may also contribute to the 
transcriptional regulation of these genes.
We also transfected cells with a cyclin B1-CAT reporter 
construct to monitor transcription initiated from the cyclin B1 
promoter. Nocodazole treatment stimulated cyclin B1-CAT ac-
tivity, which is inhibited by coexpression of dnERK5 (Fig. 9 E). 
Collectively, these data suggest that the ERK5–NFκB signaling 
pathway regulates expression of several genes key to the control 
of G2–M transition.
ERK5–NF𝗋B signaling is required for G2–M 
progression in cultured primary 
human cells
We used human artery smooth muscle cells (hSMCs) and human 
foreskin fi  broblast (HFF) cells to investigate whether the ERK5–
NFκB signal transduction system is also required for G2–M pro-
gression in nonimmortalized, nontransformed, primary human cells. 
Figure 7.  Inhibition of NF𝗋B from G2–M onwards delays mitotic entry. 
HeLa cells were released from a double-thymidine block. (A). FACS analy-
sis of the cell cycle. 2 μM helenalin or vehicle control was added 6 h after 
thymidine release to inhibit NFκB from G2 onward. (B) Addition of helen-
alin (HEL) at the start of G2 inhibits mitotic entry in the presence of 1 μM 
taxol. (C) Addition of helenalin at the start of G2 inhibits mitotic entry in 
the presence of 0.5 μg/ml nocodazole. (D) Time course of adenovirus-
mediated expression of IκB SR. (E) Expression of IκB SR from G2 onward 
delays mitotic entry. Double-thymidine block–synchronized HeLa cells 
were infected with IκB SR or control viruses at the time of thymidine 
release. Cells were incubated in medium ± 1 μM taxol. (F) FACS analysis 
of the cell cycle after IκB SR expression. HeLa cells were synchronized 
and infected with viruses as in E. Data are presented as means ± SEM.JCB • VOLUME 177 • NUMBER 2 • 2007  260
ERK5 was activated in M phase–arrested hSMCs and HFF cells, 
an activation manifested as a phosphorylation shift of ERK5 
(p-ERK5) in nocodazole-treated cells (M; Fig. 10, A and B). 
Signifi  cantly, expression of adenoviral dnMEK5 or IκB SR 
  reduced the mitotic index in hSMC (Fig. 10 C). Inhibition of 
NFκB activity by SN50 or helenalin signifi  cantly reduced mitotic 
index in HFF cells (Fig. 10 D). These results implicate a role for 
the ERK5–NFκB signal pathway in G2–M progression during 
the cell cycle of primary human cells.
Discussion
Although regulation of the G1 phase has been extensively inves-
tigated, much less is known about regulation of the G2–M phase 
transition. Besides a requirement for cyclin B and cdc2 activa-
tion, few other genes or signaling molecules have been identifi  ed 
for the control of the G2–M transition. Here, we discovered that 
ERK5 is activated at G2–M and is critical for the G2–M transi-
tion and timely mitotic entry. This function requires ERK5 acti-
vation of NFκB through RSK2. Furthermore, NFκB regulates the 
expression of several genes essential for mitosis, including cyclin 
B1, cyclin B2, Plk-1, and cdc25B. We also observed the activa-
tion and requirement of the ERK5–NFκB pathway for the G2–M 
progression in primary cultured human cells. These data suggest 
a novel function for the ERK5–NFκB pathway in regulation of 
the G2–M transition in both primary and transformed cells.
To investigate the functional signifi  cance of ERK5 activa-
tion at G2–M, we performed several types of experiments to ex-
amine the effects of blocking or stimulating ERK5 activity on 
mitosis. Constitutive activation of the ERK5 pathway was suffi  -
cient to increase the mitotic index in an asynchronous cell popu-
lation, whereas blocking ERK5 activity with dnERK5 or siRNA 
reduced mitotic index in S phase–synchronized HeLa cells. 
Most important, expression of adenoviral dnMEK5 from G2 
onward, which eliminates potential interference of ERK5 sig-
naling at G1 or S phase of the cell cycle, reduced mitotic index. 
These data are the fi  rst report of a causal relationship between 
ERK5 activation and G2–M progression.
Although ERK5 had been implicated in cellular prolifera-
tion, the underlying mechanisms were not defi  ned. It has been 
reported that ERK5 regulates the G1–S transition of the cell cycle; 
however, evidence supporting this hypothesis is controversial. 
For example, some reports showed that dnMEK5 inhibition 
of ERK5 in NIH 3T3 cells blocks EGF stimulation of thymi-
dine incorporation (Kato et al., 1998) and ERK5 may activate 
cyclin D1 expression (Mulloy et al., 2003). In contrast, although 
MEK5 knockout mice have a phenotype similar to the ERK5-null 
mice, mouse embryonic fi  broblast cells derived from MEK5
−/− 
mice do not exhibit a defect in G1–S (Wang et al., 2005). Our 
data demonstrate that ERK5 phosphorylation is barely detect-
able in HeLa cells arrested at G1 or S phase when HeLa cells 
are released from a thymidine block. This is consistent with 
the report by Wang et al. (2005) arguing against a role for 
ERK5 in G1–S regulation. Thus, ERK5 may regulate cellular 
proliferation primarily through its action at the G2–M phases of 
the cell cycle.
What are the downstream targets that mediate ERK5 regu-
lation of the G2–M transition? Our data showed that NFκB 
is activated when cells were arrested at the start of M phase by 
Figure 8. NF𝗋B is required for ERK5 to promote G2–M progression. HeLa 
cells were transiently transfected with a vector control (Vec) or caMEK5 + 
ERK5 to activate ERK5 signaling. 1 d after transfection, cells were arrested 
at S phase with a single-thymidine block. (A) Cells were infected with IκB 
SR or a control adenovirus 2 h after thymidine release. (B) SN50, the con-
trol peptide (CON), or 1 μM helenalin (HEL) was added 8 h after thymi-
dine release. Mitotic index in transfected cells was determined 12 h after 
thymidine release. Data are presented as means ± SEM. **, P < 0.01; 
***, P < 0.001.
Figure 9. NF𝗋B regulates transcription of G2–M speciﬁ  c genes. (A–D) 
Transcription of cyclin B1, cyclin B2, Plk-1, and cdc25B at G2–M is inhib-
ited by IκB SR expression. HeLa cells were infected with control or IκB SR 
adenoviruses at the time of release from a double-thymidine block. Non–
virus infected, double-thymidine–blocked cells were used as a control. 
Total RNA was prepared 9 h after thymidine release for quantitative RT-PCR. 
(E) Nocodazole stimulates cyclin B promoter activity in an ERK5-dependent 
manner. HEK293 cells were cotransfected with a cyclin B1-CAT re-
porter gene and dnERK5 or vector control (Vec). 36 h later, cells were 
treated with nocodazole for 12 h. Error bars indicate SD. *, P < 0.05; 
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nocodazole treatment, 12 h after thymidine release, or in mitotic 
shake-off cells. Furthermore, NFκB activation in G2–M re-
quires ERK5 activity. Inhibition of NFκB starting from G2 
phase onward, achieved by treatment with helenalin or SN50, or 
by expression of adenoviral IκB SR, reduced the mitotic index. 
The delay in the rate of appearance of mitotic cells was also 
  observed when mitotic exit was blocked by taxol or nocodazole, 
suggesting a pivotal role for NFκB in timely mitotic entry. 
In addition, stimulation of mitosis in cells transfected with 
caMEK5 + ERK5 was suppressed by inhibiting NFκB from G2 
onward, demonstrating a direct link between ERK5 and NFκB 
at G2–M. These data suggest a novel function for the ERK5–
NFκB pathway in the regulation of G2–M transition.
The transition from G2 to M phase requires activation of 
the cyclin B–cyclin-dependent kinase 1 (CDK1, also known as 
cdc2) complex (Nurse, 2000). The cyclic activation of this com-
plex at G2–M is stimulated by dephosphorylation of CDK1 and 
increased expression of cyclin B. This process is regulated by 
several G2–M kinases and phosphatases, including cdc25 and 
Plk (Nilsson and Hoffmann, 2000; Barr et al., 2004). The activ-
ity and expression of cdc25 and Plk are also regulated in a cell 
cycle–dependent manner. Although it is clear that many of these 
G2–M regulators are controlled transcriptionally in a cell  cycle–
specifi  c manner, mechanisms underlying their transcriptional 
regulation are not well defi  ned. Recently, it was reported that 
the forkhead family of transcription factors, including FOXM1 
and FoxO, play a critical role in the expression of genes impor-
tant for mitotic entry and exit (Alvarez et al., 2001; Laoukili 
et al., 2005). In this study, we discovered that blocking NFκB 
signaling at G2–M inhibits transcription of cyclin B1, cyclin B2, 
Plk-1, and cdc25, suggesting an important role for NFκB in 
the transcriptional regulation of these genes. These fi  ndings 
provide new insights concerning transcriptional mechanisms 
governing G2–M progression of the cell cycle. Although NFκB 
has been implicated in cell proliferation and many forms of 
  human cancer, NFκB activity has only been implicated in regu-
lation of the G1–S phases of the cell cycle through induction of 
the G1 cyclin, cyclin D (Guttridge et al., 1999; Hinz et al., 1999). 
Our study identifi  es a new function for NFκB in the regulation 
of G2–M transition.
It has been reported that forced activation of ERK5 stimu-
lates NFκB reporter gene expression; however, the mechanism 
by which ERK5 activates NFκB was not elucidated (Pearson 
et al., 2001). NFκB-mediated transcription can be stimulated by 
increased DNA binding or by an NFκB phosphorylation that 
enhances the recruitment of transcriptional coactivators (Wang 
et al., 2000). However, we found that ERK5 does not directly 
stimulate Gal-4–NFκB–mediated transcription (unpublished 
data). Instead, IκB protein was degraded and NFκB DNA binding 
activity increased in M phase–arrested cells; both processes 
required ERK5 activity. These data support the hypothesis that 
NFκB activation at G2–M is mediated by ERK5 stimulation of 
IκB degradation and subsequent NFκB binding to DNA.
Previous studies showed that NFκB activation by no-
codazole requires IKK in some cells and that this promotes 
cell survival after mitotic cell cycle arrest (Mistry et al., 2004). 
Surprisingly, IKK was not active at G2–M, when HeLa cells 
were released from a thymidine block, or in a cell population 
  enriched for mitotic cells. Thus, although IKK may counteract 
nocodazole-induced apoptosis by acting as an IκB kinase in 
some cells, it does not mediate ERK5 activation of NFκB 
during G2–M progression of the cell cycle.
RSK1 and RSK2 both phosphorylate IκB (Ghoda et al., 
1997; Schouten et al., 1997). However, ERK5 stimulated the 
activity of RSK2, but not RSK1. Furthermore, RSK2 was acti-
vated at G2–M and physically associated with ERK5. Constitu-
tive activation of ERK5 promoted RSK2 phosphorylation of 
IκB, whereas blocking ERK5 reduced the kinase activity of 
RSK2 toward IκB. Moreover, RSK2 activity was required for 
NFκB activation induced by ERK5 or M phase arrest. Expres-
sion of dnRSK2 blocked mitotic entry of HeLa cells induced by 
ectopic ERK5 activation. These results suggest that RSK2 is 
necessary for ERK5-induced degradation of IκB at G2–M. 
However, RSK2 phosphorylates IκB on S32, but not S36, which 
is necessary but not suffi  cient for IκB degradation (Beg et al., 
1992; Liu et al., 1996). Thus, it is likely that, in addition to 
RSK2, ERK5-mediated phosphorylation of IκB may require 
Figure 10. ERK5–NF𝗋B signaling is required for G2–M progression in 
cultured primary human cells. (A and B) ERK5 Western analysis demonstrating 
that ERK5 is activated in primary hSMCs (A) and HFF cells (B) arrested 
with nocodazole at M phase. (C) Inhibition of ERK5 or NFκB signaling re-
duces mitotic index in hSMCs. Cells were synchronized at S phase by a 
single-thymidine block and infected with dnMEK5, IκB SR, or control adeno-
viruses 2 h after thymidine release. Mitotic index was scored 12 h after thy-
midine release (i.e., 10 h after infection). Minus sign indicates no virus. UT, 
untreated. (D) Inhibition of NFκB reduces mitotic index in HFF cells. Cells 
were synchronized at S phase by a single-thymidine block. To inhibit NFκB 
signaling starting from G2, cells were treated with 18 μM SN50, 1 μM 
helenalin, or control peptide (CON) 5 h after thymidine release. Mitotic 
index was determined 9 h after thymidine release. (E) Hypothesis model for 
ERK5 regulation of G2–M progression. Based on data presented in this 
study, we propose that ERK5 activation of RSK2 at G2–M promotes IκB 
phosphorylation and degradation. This leads to NFκB nuclear transloca-
tion and induction of NFκB target genes that are required for the G2–M 
progression. Data are presented as means ± SEM. ***, P < 0.001.JCB • VOLUME 177 • NUMBER 2 • 2007  262
another, unidentifi  ed kinase that mediates ERK5 phosphoryla-
tion of IκB at S36.
We were unable to achieve complete inhibition of mitotic 
entry by blocking ERK5, RSK2, or NFκB, possibly because 
none of the experimental approaches completely blocked the 
signaling events, or there may be additional pathways involved. 
Furthermore, because inhibition of NFκB delays but does not 
completely halt mitotic progression (Fig. 7), it is possible that 
the ERK5–RSK2–NFκB signaling pathway plays a regulatory 
rather than obligatory role in the G2–M cell cycle control as ex-
emplifi  ed by FoxM1 (Laoukili et al., 2005).
In summary, we propose that ERK5 is activated at G2–M 
and that it stimulates downstream kinases, including RSK2 
kinase (Fig. 10 E). RSK2 phosphorylates IκB, targeting it for 
degradation, thereby releasing NFκB from IκB. Subsequently, 
NFκB translocates to the nucleus and activates expression of 
target genes that are required for the G2–M progression. Our 
studies identify an unexpected and novel role for the ERK5–
NFκB pathway in G2–M regulation.
Materials and methods
Materials
HEK293 and HeLa cells were purchased from American Type Culture Col-
lection. HEK293 cells were used for reporter gene assays and NFκB DNA 
binding assays because the basal NFκB activity is very high in HeLa cells. 
However, for ﬂ  ow cytometry and immunocytochemistry, HeLa cells were 
routinely used because HEK293 cells grow in clusters and clumps, making 
it difﬁ  cult to analyze by these assays. Primary hSMCs were provided by 
B. Askari and K. Bornfeldt (University of Washington, Seattle, WA; Renard 
et al., 2003). HFF cells were provided by A. Minella and B. Clurman (Fred 
Hutchinson Cancer Research Center, Seattle, WA; Minella et al., 2002). 
A commercial siRNA to human ERK5 and control nonsilencing RNA (NS) 
were obtained from Ambion. The following plasmids were obtained from 
J.D. Lee (The Scripps Research Institute, La Jolla, CA): wt and dnERK5 and 
HA-tagged caMEK5 (Kato et al., 1997). The ﬂ  ag-tagged dnRSK2 construct 
was a gift from S. Impey (Oregon Health Sciences University, Portland, 
OR). The cyclin B1-CAT (pB1-CAT) reporter plasmid was provided by 
G. Piaggio and C. Gaetano (CRS-IRE, Rome, Italy; Piaggio et al., 1995). The 
dnMEK5 adenovirus was a gift from R. Segal (Dana Farber Cancer Insti-
tute, Boston, MA). The NFκB-luciferase reporter and IκB SR adenovirus 
have been described previously (Wang et al., 1996). The polyclonal anti-
body to ERK5 was generated in our laboratory (Cavanaugh et al., 2001). 
The following antibodies were obtained commercially: anti-RSK2, anti–
phospho-histone H3 (Ser10), and anti–phospho-MPM-2 (Upstate Biotech-
nology), anti–phospho-IκB Ser32 or Ser36 (Calbiochem), anti–phospho-
IKK Ser180/181 and anti-IκB (Cell Signaling Technologies), anti-MEK5 
antibody (Santa Cruz Biotechnology, Inc.), and anti-ERK1/2 antibody 
(Promega). Cell-permeable NFκB inhibitor SN50 and control peptides, 
helenalin, thymidine, nocodazole, taxol, and aphidicolin were purchased 
from Calbiochem. Hoechst 33342 was obtained from Sigma-Aldrich. 
  Myelin basic protein (MBP) was purchased from Upstate Biotechnology.
Transient DNA/siRNA transfection
HeLa or HEK293 cells (10
6 cells/60-mm dish) were transiently transfected 
with plasmid DNA by Fugene 6 (Roche). siRNA was transiently transfected 
using Oligofectamine (Invitrogen).
Cell cycle synchronization
HEK293, HeLa, and HFF cells were arrested in different cell cycle phases 
as follows: serum withdrawal for 14 h followed by addition of serum for 1 h 
(G1), 1 μg/ml aphidicolin (G1–S; 12 h), 2 mM thymidine (S; 14–16 h), 
or 0.5 μg/ml nocodazole (M; 12 h). Cell cycle arrest was conﬁ  rmed by 
ﬂ  ow cytometry analysis. Primary hSMCs were arrested using similar drug 
treatments for 14 h. Initially, cells were synchronized at early S phase by a 
single-thymidine block, in which cells were treated with 2 mM thymidine for 
15 h, released from the block by washing cells in PBS three times, and 
grown in complete medium for the indicated times up to 12 h. In later 
  experiments, a double-thymidine block was used to obtain better syn-
chrony. Cells were treated with 2 mM thymidine for 16 h and released for 
8 h, followed by an additional 16-h thymidine block and release. The cells 
were then washed three times with PBS and released into complete me-
dium. To examine the effect of adenoviral gene expression or drug treat-
ment on mitosis, NFκB inhibitors and adenoviruses were added at the 
indicated times after ﬁ  nal thymidine release.
Reporter gene assays
HEK293 cells were transfected using Fugene 6 by the manufacturer’s 
instructions. In brief, 0.15 ×10
6 cells were plated onto each well of a 
24-well plate coated with poly-D-lysine (Sigma-Aldrich). After 24 h, cells 
were transfected with the appropriate reporter genes (0.36 μg/well NFκB-
luciferase plus 0.05 μg/well EF1α-lacZ plasmid DNA). Where indicated, 
cells were cotransfected with 0.16 μg/well dnERK5. Cells were treated 
48 h   after transfection, and luciferase and β-galactosidase activities 
were measured. For the cyclin B1-CAT reporter assay, HEK293 cells were 
  cotransfected with a plasmid encoding dnERK5, the reporter plasmid pB1-
CAT, and an EF1α-lacZ plasmid as an internal control. Cell lysates were 
harvested 48 h after transfection, and CAT activity was assayed in whole-
cell extracts as described previously (Piaggio et al., 1995). The reporter 
gene luciferase or CAT activities were normalized to β-galactosidase activ-
ity and expressed as the fold induction relative to control.
NF𝗋B DNA binding assay (assay for p50–p65 DNA binding)
Nuclear fractions were prepared from cell lysates of HEK293 cells using 
the NucBuster Protein Extraction kit (Novagen) per the manufacturer’s 
instructions. Nuclear NFκB DNA binding activity (the p50–p65 complex) 
was then quantitated by the NFκB Transcription Factor Assay ELISA kit 
(Chemicon International) per the manufacturer’s instructions. The DNA 
binding activity of NFκB was also measured by an electrophoretic mobility 
shift assay (gel shift) as described previously (Wang et al., 1996).
Cell cycle analysis
Except where speciﬁ  ed, mitotic cells were scored by nuclear condensation 
in conjunction with positive staining for p-MPM-2, a mitotic marker. In Fig. 
3 A, p-histone H3 was used as another mitotic marker in addition to 
p-MPM-2. Alternatively, HeLa cells in G1 (2n DNA) or G2–M (4n DNA) were 
quantitated by ﬂ  ow cytometry analysis (FACS). In brief, cells were trypsin-
ized, resuspended in ice-cold 70% ethanol, and ﬁ  xed at 4°C for 30 min. 
Cells were then resuspended in propidium iodide staining buffer containing 
200 μg/ml RNase and 2% FBS in 1× PBS and incubated at 4°C for 3 h. 
Cells were then resuspended in PBS/2% FBS with an 18-gauge needle 
and analyzed by FACScan analyzer (Becton Dickinson) equipped with a 
518-nm laser.
In vitro kinase assays
Cell lysates were prepared from HeLa cells as described previously (Xia 
et al., 1995). Equal amounts of protein lysates (350 μg) were used for 
each kinase assay. The kinase activities for ERK5 or MEK5 were measured 
using immunoprecipitation-coupled in vitro kinase assays using recombi-
nant GST-MEF2C or MBP as substrates, respectively (Cavanaugh et al., 
2001; Wang et al., 2006). To measure endogenous RSK2 activity, cell ly-
sates were immunoprecipitated with a polyclonal anti-RSK2 antibody. In 
brief, 5 μg anti-RSK2 antibody was incubated with 50 μl protein A–
Sepharose beads overnight at 4°C. The beads were washed once with lysis 
buffer and then incubated with cell lysates for 3 h at 4°C. RSK2 kinase ac-
tivity in the immune precipitates was then quantitated by evaluating the in-
corporation of [
32P]ATP into either 0.1 mM CREBtide (Sigma-Aldrich; Impey 
et al., 1998) or 1 μg of a recombinant human IκB protein (BIOMOL 
  Research Laboratories, Inc.).
Quantitative RT-PCR
Total RNA was isolated using RNeasy Miniprep kit (QIAGEN). To remove 
trace genomic DNA, DNA-free (Ambion) treatment was performed on 
samples. Total RNA was quantitated on the Mx4000 Multiplex QPCR System 
(Stratagene) using the RiboGreen RNA Quantitation kit (Invitrogen). Quan-
titative RT-PCR was performed in a single reaction on an Mx4000 Multi-
plex QPCR System using 20 ng of total RNA. The RT-PCR reactions were 
performed in triplicates in a 20-μl reaction using SYBR Green PCR Master 
Mix (Applied Biosystems; 10 μl 2× Master Mix, 400 nM each primer, 
5 U MultiScribe RT, and 8 U RNase inhibitor). The   cycling conditions were 
48°C for 30 min and 95°C for 10 min, followed by 40 cycles of 95°C for 
15 s and 60°C for 1 min. After each assay, a dissociation curve was run 
to conﬁ  rm speciﬁ  city of all PCR amplicons. Resulting Ct values were con-
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of triplicate samples ± SD. Pooled sample   total RNA was used for stan-
dard curves as 1:2 serial dilutions. The standard curves showed reaction 
efﬁ  ciencies as follows: hcdc25B, 102.6% and R
2 = 0.999; hPLK1, 102.5% 
and R
2 = 0.998; hCCNB1, 100.6% and R
2 = 0.998; and hCCNB2, 
101.3% and R
2 = 0.998. PCR primers were designed using Primer Ex-
press 2.0 software (Applied Biosystems) and synthesized by Operon. The 
sequences were as follows: hcdc25B, forward, C  C  C  T  A  T  G  G  A  C  C  C  C  C  A-
C  A  T  G  , and reverse, A  T  G  G  C  A  A  A  C  T  G  C  T  C  G  T  T  T  C  G  ; hPlk1, forward, G  A  G  C  G-
T  G  A  C  G  G  C  A  C  T  G  A  G  T  , and reverse, A  A  G  G  A  G  G  G  T  G  A  T  C  T  T  C  T  T  C  A  T  C  A  A  ; 
hcyclinB1, forward, G  A  A  A  T  G  T  A  C  C  C  T  C  C  A  G  A  A  A  T  T  G  G  T  , and reverse, 
C  C  A  T  C  T  G  T  C  T  G  A  T  T  T  G  G  T  G  C  T  T  A  G  ; hcyclinB2, forward, T  G  T  C  A  A  C  A  A  A  C-
A  A  C  T  G  A  A  A  C  C  T  A  C  T  G  , and reverse, C  C  T  C  A  G  G  T  G  T  G  G  G  A  G  A  A  G  G  A  .
Microscopy
For Fig. 3 D, images were collected with an inverted ﬂ  uorescence micro-
scope (Leitz DMIRB; Leica) using a 40× objective lens (Leitz; Leica). Magna-
Fire digital microscope camera and MagnaFire software (Optronics, Inc.) 
were used for system control and image processing. For Fig. 1 B and Fig. 
5 E, images were taken by a Marianas imaging system (Intelligent Imaging 
Innovations, Inc.) incorporating a microscope (Axiovert 200M; Carl Zeiss 
MicroImaging, Inc.) with an X,Y motorized stage, shuttered 175 W xenon 
lamp coupled with a liquid light guide, a digital camera (CoolSNAP HQ; 
Roper Scientiﬁ  c), and 40× objective lens (Axiovert; Carl Zeiss MicroImag-
ing, Inc.). Slidebook software package was used for system control and 
image processing.
Statistical analysis
Results were from three or more independent experiments. Data are pre-
sented as means ± SEM for all except in Fig. 9, in which error bars are 
SD. We used two-tailed t test assuming equal variance for statistical analysis 
of the data. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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